BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Dynamic Nanomaterials for Drug Delivery and Diagnostics
DTSTART:20130515T153000
DTEND:20130515T163000
DTSTAMP:20260405T201725Z
UID:7b30d4fdbe9f33a26b06bb18704fd85f535200294479aa6a9d0898a5
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Patrick Stayton\, University of Washington\, Seattle\, W
 A (USA)\nBio: Dr. Stayton is the director of the Institute for Molecular E
 ngineering and Sciences and the Center for Intracellular Delivery of Biolo
 gics. He received his B.S. in biology (summa cum laude) from Illinois Stat
 e University\, his Ph.D. in biochemistry from the University of Illinois\,
  and he was a postdoctoral research associate at the Beckman Institute for
  Advanced Science and Technology\, also at the University of Illinois.\nDr
 . Stayton’s eclectic research group works at the interface of fundamenta
 l molecular science and applied molecular bioengineering. His laboratory h
 as pioneered new drug delivery systems for biologic drugs and vaccines and
  new nanotechnologies for diagnostic and regenerative technologies. Dr. St
 ayton has a strong interest in translating the group’s research\, has be
 en awarded several patents\, and is a co-founder of two start-up companies
 : PhaseRx Inc.\, based on his group’s drug delivery work\, and Nexgenia\
 , based on their diagnostic work.\nDr. Stayton has been elected as a fello
 w of the American Institute for Medical and Biological Engineering and has
  received the Clemson Award from the Society for Biomaterials and the CRS-
 Cygnus Recognition Award from the Controlled Release Society. He served as
  co-chair of the Gordon Conference on Drug Carriers in Medicine and Biolog
 y in 2010. He has also been awarded the 2009 Faculty Research Innovation A
 ward in the UW College of Engineering\, a Distinguished Teacher and Mentor
  Award from the Department of Bioengineering\, and an honorary award from 
 the College of Engineering’s Minority Science and Engineering Program.\n
 Our group develops stimuli-responsive nanomaterials that utilize dynamic s
 tructural and architectural transitions to enable new drug delivery and di
 agnostic functionalities.  For drug delivery applications we are focused 
 on opening the intracellular target universe to biologic drugs.  Biologic
  drugs such as DNA\, RNA and proteins have significant therapeutic potenti
 al\, but effectively formulating and delivering them remains a widely reco
 gnized challenge. Barriers include drug stability\, tissue penetration and
  transport\, but cytoplasmic entry is a widespread barrier for those that 
 function against intracellular disease targets. We have been developing sy
 nthetic polymeric carriers that mimic the highly efficient intracellular d
 elivery systems found in pathogenic viruses and organisms. Another importa
 nt aspect of these polymeric carriers is the development of controlled pol
 ymerization techniques to streamline bioconjugation of targeting agents an
 d therapeutics\, as well as to generate controlled carrier architectures. 
 The carriers might open up new families of peptide\, antibody or nucleic a
 cid drug candidates that attack previously inaccessible intracellular targ
 ets. For diagnostic applications we are addressing the technology gap for 
 making clinical assays faster and more sensitive\, as well as the need for
  simple yet efficient sample handling techniques that concentrate dilute b
 iomarkers for point-of-care (POC) tests. We have developed a new stimuli-r
 esponsive magnetic nanoparticle reagent system for achieving both of these
  goals. These new bioanalytical systems are being applied to clinical lab 
 assays\, lab card disposable devices and for non-instrumented lateral flow
  diagnostic platforms.
LOCATION:SV1717a http://map.epfl.ch/?room=sv1717a
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR